(C) Reuters. FILE PHOTO: A COVID-19 self-test kit is seen before being used by a teacher in Milton Keynes, Britain, January 28, 2021. REUTERS/Andrew Boyers
(Reuters) -Shares of Biotech group Oxford Nanopore Technologies soared more than 30% within minutes of their market debut on Thursday, indicating increased investor interest in life sciences companies listing in London.
The stock was trading at 568 pence by 0730 GMT and the company’s valuation was about 4.51 billion pounds ($6.17 billion). The offer price was 425 pence.
The listing marks a significant move for the London Stock Exchange as most British pharma and life science companies tend to list on New York’s Nasdaq.
The company, which specialises in DNA sequencing and provides rapid COVID-19 tests to Britain’s national health services, sold 524 million pounds worth of shares in the IPO. It set its issue price towards the upper end of an earlier range.
It had planned to issue 82.4 million new shares, raising 350 million pounds, while existing shareholders sold 41 million shares, it said in a statement.
($1 = 0.7311 pounds)
Oxford Nanopore valued at $6.17 billion as shares soar in London debut
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.